<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-162904</identifier>
<setSpec>0214-9168</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease</dc:title>
<dc:description xml:lang="en">Non-alcoholic fatty liver disease (NAFLD) comprises a series of histologically lesions similar to those induced by alcohol consumption in people with very little or no liver damage. The importance of NAFLD is its high prevalence in the Western world and, from the point of view of the liver, in its gradual progression from steatosis to steatohepatitis, cirrhosis, and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with acceleration of arteriosclerosis and events related to it, being the main cause of its morbidity and mortality. This review, updated to January 2016, consists of two parts, with the first part analysing the association of NAFLD with cardiovascular disease (AU)</dc:description>
<dc:creator>Díaz, Ángel</dc:creator>
<dc:creator>Hernández Mijares, Antonio</dc:creator>
<dc:creator>Pintó, Xavier</dc:creator>
<dc:creator>Millán, Jesús</dc:creator>
<dc:creator>Pedro-Botet, Juan</dc:creator>
<dc:creator>Brea, Ángel</dc:creator>
<dc:creator>Ascaso, Juan F</dc:creator>
<dc:creator>Blasco, Mariano</dc:creator>
<dc:creator>González Santos, Pedro</dc:creator>
<dc:creator>Mantilla, Teresa</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La enfermedad del hígado graso no alcohólico (EHGNA) comprende una serie de lesiones hepáticas histológicamente similares a las inducidas por el alcohol, en personas con un consumo del mismo muy escaso o nulo. La importancia de la EHGNA radica en su alta prevalencia en el mundo occidental y, desde el punto de vista hepático, en su progresiva evolución desde esteatosis a esteatohepatitis, cirrosis y cáncer de hígado. Durante la última década se ha observado que la EHGNA da lugar a un incremento del riesgo cardiovascular con aceleración de la arteriosclerosis y de los eventos a ella vinculados, principal causa de su morbimortalidad. Esta revisión actualizada a enero de 2016 consta de dos partes, analizando en esta primera parte la asociación de la EHGNA con la enfermedad cardiovascular (AU)</dc:description>
<dc:source>Clín. investig. arterioscler. (Ed. impr.);29(3): 141-148, mayo-jun. 2017. tab</dc:source>
<dc:identifier>ibc-162904</dc:identifier>
<dc:title xml:lang="es">Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (I). Enfermedad del hígado graso no alcohólico y su asociación con la enfermedad cardiovascular</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d2381^s29166</dc:subject>
<dc:subject>^d54003^s29166</dc:subject>
<dc:subject>^d50504^s22080</dc:subject>
<dc:subject>^d23568^s22002</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d5337^s22012</dc:subject>
<dc:subject>^d2359^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201706</dc:date>
</metadata>
</record>
</ibecs-document>
